Press release
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
− Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® (33% Growth vs. Same Period Last Year) – −
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® (33% Growth vs. Same Period Last Year) –\n\n− Received FDA Approval of AMVUTTRA™ (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults –\n\n− Expects to Report Topline Results from APOLLO-B Phase 3 Trial of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Within the Next Three Weeks –\n\n– Reiterated 2022 Financial Guidance, Including Combined Net Product Revenues of $870-$930 Million –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2022 and reviewed recent business highlights.\n\n“We’re pleased with our second quarter results which delivered strong growth in both patient demand and product revenues. A notable achievement in the quarter was the recent approval of AMVUTTRA, which becomes our fifth RNAi therapeutic approved in under four years, and marks our continued progress in building a multi-product TTR franchise. We’re excited to have initiated the U.S. launch and look forward to potential additional global approvals and subsequent rollout,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. “We are also eager for a number of important milestones over the rest of the year, including topline results from the APOLLO-B Phase 3 study of patisiran in ATTR amyloidosis with cardiomyopathy patients, which we’ve announced today are expected within the next three weeks. Additionally, we plan to continue to advance our robust pipeline, with clinical data expected across several prevalent disease programs in NASH, HBV, gout, and early-onset Alzheimer’s disease with ALN-APP, our first investigational RNAi therapeutic targeting a CNS disorder. We believe the first half of 2022 has been one of steady progress and commercial execution, and we look forward to the many important milestones through the end of the year, moving us further along our path toward achieving our Alnylam P5x25 goals.”\n\n\nSecond Quarter 2022 and Recent Significant Corporate Highlights\n\nCommercial Performance\n\nTTR Franchise: ONPATTRO® (patisiran) & AMVUTTRA™ (vutrisiran)\n\n\nAchieved global net pro...